AstraZeneca PLC Files 6-K on Director Shareholdings

TL;DR

AZN insiders are reporting their stock holdings, standard disclosure.

AI Summary

AstraZeneca PLC filed a Form 6-K on June 12, 2025, reporting its shareholding information for Directors and Persons Discharging Managerial Responsibility (PDMRs) for the month of June 2025. The filing is made pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.

Why It Matters

This filing provides transparency into the share ownership of key company insiders, which can be an indicator of their confidence in the company's future performance.

Risk Assessment

Risk Level: low — This is a routine disclosure of insider shareholdings, not indicative of new risks or significant events.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• 001-11960 (company) — SEC File Number
• June 2025 (date) — Reporting period
• Rule 13a-16 (legal_document) — Reporting rule
• Rule 15d-16 (legal_document) — Reporting rule

FAQ

From the Filing

0001654954-25-006868.txt : 20250612 0001654954-25-006868.hdr.sgml : 20250612 20250612104647 ACCESSION NUMBER: 0001654954-25-006868 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250612 FILED AS OF DATE: 20250612 DATE AS OF CHANGE: 20250612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251042017 BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a4851m.htm DIRECTOR/PDMR SHAREHOLDING a4851m FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of June 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________         AstraZeneca PLC   INDEX TO EXHIBITS     1. Director/PDMR Shareholding     12 June 2025   Transaction by Person Discharging Managerial Responsibilities   AstraZeneca PLC (the Company) announces that, on 11 June 2025, it was notified by Aradhana Sarin, Executive Director and Chief Financial Officer, that, on 10 June 2025, Dr Sarin ceased to be beneficially interested in 200 American Depositary Shares (ADSs) of the Company, following the gift of those shares to charity for nil consideration. Each ADS represents one half of an ordinary share of $0.25 each in the Company.   Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).     1   Details of the person discharging managerial responsibilities / person closely associated a)   Name Aradhana Sarin 2   Reason for the notification   a)   Position/status   Chief Financial Officer b)   Initial notification/Amendment Initial notification 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a)   Name AstraZeneca PLC b)   LEI PY6ZZQWO2IZFZC3IOL08 4i   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a)   Description of the financial instrument, type of instrument   Identification code AstraZeneca PLC American